摘要
目的探讨他克莫司联合小剂量糖皮质激素治疗合并HBsAg阳性的原发性。肾病综合征的临床效果。方法抽取2015年1月至2016年1月本院62例合并HBsAg阳性原发性肾病综合征患者，根据治疗方案不同分为对照组（n=31）与研究组（n=31）；对照组仅采用强的松，研究组联合采用小剂量强的松与他克莫司，两组均持续治疗6个月；统计两组临床疗效、不良反应发生率，对比治疗前后两组血常规及尿常规相关指标[血肌酐（Scr）、尿素氮（BUN）、血清白蛋白（ALB）、血浆总蛋白（TP）、24h尿蛋白（Upro）]水平变化情况。结果研究组总有效率（90．32％）高于对照组（67．74％），不良反应发生率（12．91％）低于对照组（38．71％），差异有统计学意义（P〈0．05）；治疗前两组Scr、BUN、ALB、TP、24hUpro水平对比差异无统计学意义（P〉0．05），经治疗，研究组ALB[（37．61±5．76）g／L]、TP[（68．64±7．87）g／L]、24hUpro[（0．62±0．35）g／L]水平明显优于对照组，差异有统计学意义（P〈0．05）。结论他克莫司联合小剂量糖皮质激素治疗合并HBsAg阳性的原发性肾病综合征效果显著，可有效改善机体功能，提高治疗效果，降低不良反应发生率。
Objective To explore the clinical effect of tacrolimus combined with low dose glucocorticoid in the treatment of HBsAg positive patients with primary nephrotic syndrome. Methods From January 2015 to January 2016, 62 HBsAg positive patients with primary nephrotic syndrome in our hospital were divided into two groups according to therapeutic regimen, 31 cases in each group. The control group was treated with prednisone only, while the study group was treated with tacrolimus combined with low-dose prednisone, both groups were treated for 6 months. The clinical efficacy and the incidence of adverse reactions were observed. The levels of serum creatinine （Scr）, blood urea nitrogen （BUN）, serum albumin （ALB）, total protein （TP）, 24 h urinary protein （Upro） were analyzed. Results The total effective rate （90.32%） in the study group was higher than that in the control group （67.74%）, and the incidence of adverse reactions （12.91%） in the study group was lower than that in the control group （38.71%） （P〈0.05）. There were no statistically significant differences in the levels of Scr, BUN, ALB, TP, and 24hUpro between the two groups before treatment （P〉0.05）; after treatment, the levels of ALB [（37.61±5.76） g/L], TP [（68.64±7.87） g/L], and 24hUpro [（0.62±0.35）g/L] in the study group were significantly better than those in the control group （P〈0.05）. Conclusions The effect of tacrolimus combined with low-dose glucocorticoid in the treatment of HBsAg positive patients with primary nephrotic syndrome is significant, which can effectively improve the body function and the treatment effect, and reduce the incidence of adverse reactions.
出处
《国际医药卫生导报》
2017年第8期1211-1213,共3页
International Medicine and Health Guidance News
